ArticleEpilepsia open2025
Long-term plasma monitoring of THC and CBD in pediatric drug-resistant epilepsy: Implications for cannabidiol therapy with Epidyolex®.
Article in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-term plasma monitoring of THC and CBD in pediatric drug-resistant epilepsy: Implications for cannabidiol therapy with Epidyolex®.Epilepsia open · 2025Article
- Accidental cannabis intoxication in two young children: clinical presentation and toxicokinetics - a case series.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated long-term plasma concentrations of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) in children receiving highly purified cannabidiol (hpCBD; Epidyolex®) therapy for drug-resistant epilepsy. A retrospective analysis was performed on 38 patients with a median age of 11 years (IQR, 5) treated in a single center from 2019 to 2024. Incremental doses of Epidyolex® (mean dose: 13.6 mg/kg/day) were administered, and plasma levels of CBD and THC were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). THC remained consistently undetectable (<0.2 μg/L) at all time points, confirming the negligible systemic exposure. CBD levels increased dose-dependently, reaching a median concentration of 89.8 μg/L (IQR, 112.2) at final follow-up, demonstrating a significant positive correlation (p < 0.0001) between dosage and plasma concentration. Epidyolex® treatment effectively maintains therapeutic CBD levels without detectable THC, supporting the safety and suitability of this therapy. These results highlight the value of plasma CBD monitoring to verify dose-dependent exposure and support safe, individualized treatment with CBD. PLAIN LANGUAGE SUMMARY: This study examined blood levels of cannabidiol (CBD) and tetrahydrocannabinol (THC) in children with drug-resistant epilepsy treated with highly purified CBD (Epidyolex). CBD levels increased proportionally with the dose, while THC levels remained undetectable. The consistent lack of THC detection across all measured time points and dose levels suggests that systemic exposure to THC remains negligible, even with prolonged administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.